MB
EPZM

MPM BioImpact’s Epizyme, Inc EPZM Stock Holding History

MPM BioImpact’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,425,202
Closed -$5.04M – 41
2022
Q2 		$5.04M Hold
3,425,202
– – 1.4% 22
2022
Q1 		$3.94M Hold
3,425,202
– – 1.06% 27
2021
Q4 		$8.56M Sell
3,425,202
-547,628
-14% -$2.15M 1.56% 18
2021
Q3 		$20.3M Buy
3,972,830
+1,641,296
+70% +$9.97M 3.16% 11
2021
Q2 		$19.4M Hold
2,331,534
– – 3.18% 10
2021
Q1 		$20.3M Hold
2,331,534
– – 2.55% 10
2020
Q4 		$25.3M Sell
2,331,534
-523,203
-18% -$6.45M 4.45% 9
2020
Q3 		$34.1M Buy
2,854,737
+523,203
+22% +$7.01M 8.21% 5
2020
Q2 		$37.4M Hold
2,331,534
– – 9.96% 5
2020
Q1 		$36.2M Hold
2,331,534
– – 22.09% 2
2019
Q4 		$57.4M Buy
+2,331,534
New +$34.6M 20.33% 2

Other funds holding EPZM

Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

MPM BioImpact's EPZM Position: Q3 2022 in Review

MPM BioImpact sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 3,425,202 shares — an estimated $5.04M sold.

MPM BioImpact first reported a position in EPZM in Q4 2019 and held it in 11 quarters. The position peaked at $57.4M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

  • MPM BioImpact reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
  • MPM BioImpact sold 3,425,202 Epizyme, Inc shares in Q3 2022, an estimated $5.04M.
  • MPM BioImpact first reported a position in Epizyme, Inc in Q4 2019 and held it in 11 quarters.
  • MPM BioImpact's Epizyme, Inc position peaked at $57.4M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on MPM BioImpact's 13F filing for Q3 2022, filed 14 Nov 2022.